MedCity News
Achilles Therapeutics’ IPO nabs $175M to bring cell therapies to solid tumors
The Achilles Therapeutics IPO comes as several other biotechs make progress developing a type of cancer immunotherapy called a tumor-infiltrating lymphocyte. Clinical-stage Achilles contends its approach could best them all.
Shares0
FDA approval of cell therapies made from a patient’s own immune cells provided another treatment option for the most serious cases of blood cancer. But this type of treatment, called CAR-T therapy, is cumbersome to manufacture and still hasn’t proven effective in solid tumors.
A different type of cell therapy called tumor infiltrating lymphocytes (TIL) could offer yet another alternative, plus the potential to address solid tumors. Several biotechs have TILs in clinical development. Achilles Therapeutics aims to best them all.
Get the latest industry news first when you subscribe to our daily newsletter.
We will never sell or share your information without your consent. See our privacy policy.
MedCity News
J.P. Morgan’s life sciences outlook for 2021
Peter Meath, J.P. Morgan Commercial Banking’s Co-Head of Healthcare and Life Sciences, applies lessons from 2020’s remarkable second half and shares insights on what to expect in 2021.
Shares0
Source: J.P. Morgan
To call 2020 a “unique year” for life sciences companies would be an understatement. The COVID-19 pandemic transformed the industry, creating immense opportunities for institutions and investors to drive healthcare through innovation.
Peter Meath, Co-Head of Healthcare and Life Sciences for Middle Market Commercial Banking at J.P. Morgan, notes that investment in life sciences reached record-high levels across almost every category and subsector despite unprecedented business challenges. Here are a few of the highlights:
MedCity News
United Therapeutics notches another FDA approval for lung drug
The FDA decision for Tyvaso as a treatment for pulmonary arterial hypertension in patients who have interstitial lung disease is the second approval for the United Therapeutics drug. The additional indication gives the company another way to grow revenue for the drug, which faces generic competition.
Shares0
United Therapeutics has received FDA approval for its drug, treprostinil, as a treatment for high blood pressure affecting the lungs in patients who have a group of rare respiratory disorders called interstitial lung diseases.
The regulatory nod is the second for the inhaled version of treprostinil, which was initially approved in 2009 as a treatment for pulmonary arterial hypertension high blood pressure in the arteries that carry blood from the heart to the lungs. Silver Spring, Maryland-based United Therapeutics also sells the drug in injectable and oral formulations. Together, the three ver
Ne portez pas d élastique trop serré autour de votre poignet slate.fr - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from slate.fr Daily Mail and Mail on Sunday newspapers.